-+ 0.00%
-+ 0.00%
-+ 0.00%
SELLAS Life Sciences Announces Topline Results From Its Phase 3 REGAL Trial Evaluating Galinpepimut-S In Patients With Acute Myeloid Leukemia Met Primary Endpoint
Share
Listen to the news

REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) -

- Company plans to meet with the U.S. Food and Drug Administration (FDA) while advancing preparations for a Biologics License Application (BLA) submission for GPS -

- SELLAS to host webcast today, November 17, 2026, at 7:45 a.m. Eastern Time -

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending